NIH R01 · 2025
The Impact of SLC26A9 on Response to CFTR Correction
PROJECT ABSTRACT / SUMMARY Although CFTR modulator therapies have improved respiratory outcomes for the Cystic Fibrosis (CF) population, the benefit to individual patients can vary widely. In “real world” studies of modulator therapies, patients continue to experience lung function decline, and as many as 1 in 5 receive no therapeutic benefit in FEV1. The factors that determine who has a strong or poor therapeutic response are not well defined, and limit both the current benefit from modulator drugs and future benefit from gene therapies. One proposed but poorly understood factor is the solute carrier SLC26A9, and specifically the risk locus rs7512462 within that gene. This locus is…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.